A new prognostic test may help determine whether a patient with prostate cancer will have a recurrence of the disease, even if surrounding lymph nodes initially appear negative for cancer, according to a study from the Keck School of Medicine at the University of Southern California, Los Angeles.
A new prognostic test may help determine whether a patient with prostate cancer will have a recurrence of the disease, even if surrounding lymph nodes initially appear negative for cancer, according to a study from the Keck School of Medicine at the University of Southern California, Los Angeles.
The test appears to be "better than anything else we know of for predicting recurrence," said lead author Richard Cote, MD, whose findings were published recently in the Journal of Clinical Oncology (2006; 24:2735-42).
Dr. Cote and colleagues examined 3,914 lymph nodes from 180 patients who were staged as having lymph nodes negative for cancer based on standardized histologic evaluation. The lymph nodes were then evaluated for occult metastases using new specific immunohistochemistry tests that can detect cancer on a cell-by-cell level.
The new analysis checks for cells that react with antibodies to cytokeratins and PSA. The team's testing found occult tumor cells in the lymph nodes of 24 of the patients whose lymph nodes previously had been diagnosed as cancer-free. The researchers then compared cancer recurrence and survival in patients with the hidden tumor cells and patients without the cells. The presence of occult tumor cells was associated with increased prostate cancer recurrence and decreased survival.
"The outcome for patients with occult tumor cells was similar to those who were identified as having positive lymph nodes at the time of the surgery," Dr. Cote said.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.